RT Journal Article
SR Electronic
T1 Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP 934
OP 936
DO 10.1111/j.1525-1438.2007.01156.x
VO 18
IS 5
A1 J. A. Rauh-Hain
A1 R. T. Penson
YR 2008
UL http://ijgc.bmj.com/content/18/5/934.abstract
AB Ovarian clear cell adenocarcinoma (OCCA) is a unique biological subtype of epithelial ovarian cancer, with a similar gene profile to renal cell carcinoma (RCC). Sunitinib is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with proven antitumor activity in RCC and a rational biological option for treatment of OCCA. A 60-year-old woman presented with recurrent and refractory stage IA OCCA, after 9 years of remission. Sunitinib was initiated as fifth-line chemotherapy, associated with cystic degeneration of liver metastasis and a short downward trend in her CA125 level. Recurrent and refractory OCCA may respond to Sunitinib. Clinical trials are needed to objectively confirm these findings, as benefit may be limited in patients with extensively pretreated tumors